Industry Webinar: A New Dawn for IgA Nephropathy – Redefining What is Possible With Sparsentan

KDIGO draft guidelines recommend that proteinuria, the only validated biomarker for disease progression in IgAN, be maintained at <0.5 g/d (preferably <0.3 g/d) to reduce the rate of kidney function loss to <1 ml/min/y. In the PROTECT phase 3 study, sparsentan reduced proteinuria and increased the proportion of pts achieving proteinuria of <0.5 or <0.3 g/d. Post-hoc analyses showed that achieving low proteinuria was predictive of better long-term kidney function, and pts once considered low risk (UPCR < 1.0 g/g) also benefited from these proteinuria reductions. Similar proteinuria reductions were observed in treatment naïve pts in the interim analyses of the phase 2 SPARTAN trial. As nephrologists consider the evolving treatment landscape and guidance, foundational nephroprotective therapies will be key to reducing proteinuria and preserving kidney function.

Learning objectives:

Describe the draft KDIGO criteria for risk of disease progression in IgAN, the proposed target proteinuria levels for preserving kidney function, and the scientific rationale for these proposed proteinuria targets
Describe the clinical benefits of achieving proteinuria remission and how sparsentan helps clinicians achieve these targets
Evaluate the evolving IgAN therapeutic landscape and where sparsentan fits into treatment in order to achieve proteinuria remission and reduce nephron loss

Further reading: